Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/389.4)
-
Publication number: 20140065165Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: October 10, 2013Publication date: March 6, 2014Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H. J. Kwaks
-
Publication number: 20140065166Abstract: The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.Type: ApplicationFiled: April 9, 2013Publication date: March 6, 2014Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.Inventors: Christopher C. Broder, Deborah L. Fusco, Kai Hu, Dimitar B. Nikolov
-
Publication number: 20140056913Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.Type: ApplicationFiled: July 25, 2013Publication date: February 27, 2014Applicant: Massachusetts Institute of TechnologyInventors: Ram Sasisekharan, Luke Nathaniel Robinson, Kannan Tharakaraman
-
Publication number: 20140056914Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: ApplicationFiled: September 30, 2013Publication date: February 27, 2014Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20140046039Abstract: Antibodies or antibody fragments, wherein the antibody or the fragment binds HA domain of influenza virus (e.g. H1N1, H5N1, or both).Type: ApplicationFiled: January 10, 2012Publication date: February 13, 2014Applicants: THE UNIVERSITY OF CHICAGO, EMORY UNIVERSITYInventors: Rafi Ahmed, Jens Wrammert, Patrick C. Wilson
-
Publication number: 20140044719Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.Type: ApplicationFiled: September 10, 2013Publication date: February 13, 2014Applicant: Crucell Holland B.V.Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Koegh
-
Publication number: 20140046034Abstract: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.Type: ApplicationFiled: October 22, 2013Publication date: February 13, 2014Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, TORAY INDUSTRIES, INC.Inventors: Takaji WAKITA, Kazumi NISHIMURA, Noriko NAKAMURA, Daisuke AKAZAWA
-
Publication number: 20140037648Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.Type: ApplicationFiled: March 14, 2013Publication date: February 6, 2014Applicant: HUMABS BIOMED SAInventor: HUMABS BIOMED SA
-
Patent number: 8637645Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides for the diagnosis and surveillance of dangerous viral infections.Type: GrantFiled: September 13, 2012Date of Patent: January 28, 2014Assignee: Temasek Life Sciences Laboratory LimitedInventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
-
Patent number: 8637644Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides for the diagnosis and surveillance of dangerous viral infections.Type: GrantFiled: September 13, 2012Date of Patent: January 28, 2014Assignee: Temasek Life Sciences Laboratory LimitedInventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
-
Publication number: 20140024017Abstract: The invention relates to the identification of a novel human polyomavirus species (designated IPPyV) and applications derived from the identified features and properties of this virus. The IPPy virus species of the invention qualifies as a human virus, in view of the fact that it is capable of infecting a human host. Having identified a novel human polyomavirus species, IPPyV, the inventors have been able to propose means for the detection of exposure or infection by such a virus, especially detection in a biological sample previously obtained from a human host. The invention also concerns means suitable for obtaining an immune response in a host with a view to prevent the onset or the development of an infection with an IPPyV.Type: ApplicationFiled: December 27, 2011Publication date: January 23, 2014Inventors: Marc Eloit, Justine Cheval, Virginie Sauvage
-
Publication number: 20130330358Abstract: Two vIRF4 (Kaposi's-sarcoma-associated-herpesvirus vIRF4) peptides, vif1, corresponding to aa202-216 of vIRF4, and vif2, corresponding to aa220-236 of vIRF4, are potent and selective HAUSP antagonists. The vif1 and vif2 peptides robustly suppress HAUSP DUB enzymatic activity, ultimately leading to p53-mediated anti-cancer activity. The vif1 and vif2 peptides, along with their homologues, are useful in treating cancer through regulation of p53 activity in a cancer cell. Also disclosed is the crystalline structure of vIRF4-HAUSP TRAF domain complex. The structure is useful in computer aided drug design for identifying an agent that interacts with and inhibits HAUSP, resulting in p53 medicated cell cycle arrest of cancer cells.Type: ApplicationFiled: February 22, 2012Publication date: December 12, 2013Inventors: Jae Jung, Hye-Ra Lee, Myung Hee Kim, Tae-Kwang Oh, Jung-Won Hwang
-
Patent number: 8604179Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: GrantFiled: April 24, 2009Date of Patent: December 10, 2013Assignees: Toray Industries, Inc., Japan As Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Organization for Medical ResearchInventors: Daisuke Akazawa, Takaji Wakita
-
Publication number: 20130309248Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.Type: ApplicationFiled: May 20, 2013Publication date: November 21, 2013Inventors: Mark Throsby, Robert H.E. Friesen, Theodorus H.J. Kwaks, Mandy A. C. Jongeneelen
-
Publication number: 20130302349Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: Visterra, Inc.Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
-
Publication number: 20130302348Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Applicant: Massachusetts Institute of TechnologyInventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
-
Publication number: 20130302350Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: April 16, 2013Publication date: November 14, 2013Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Patent number: 8574830Abstract: Monoclonal antibodies and related binding proteins specific to influenza H5 subtype HA protein can be used in serological diagnosis of influenza H5 infection in mammalian and avian serum samples, including human serum samples. Each antibody reacts strongly with a wide variety of strains of H5 subtype and does not show cross-reactivity with non-H5 influenza subtypes.Type: GrantFiled: February 5, 2008Date of Patent: November 5, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Prabakaran Mookkan, Nayana Prabhu Padubidhri, Sumathy Velumani, Hwei-Sing Jimmy Kwang
-
Patent number: 8557241Abstract: Compositions and methods for the treatment and prevention of pox virus infections are disclosed.Type: GrantFiled: May 26, 2010Date of Patent: October 15, 2013Assignee: The Institute for Cancer ResearchInventors: Luis J. Sigal, Ren-Huan Xu
-
Publication number: 20130251715Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus H5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Applicants: NATIONAL INSTITUTE OF HEALTH RESEARCH AND DEVELOPMENT (NIHRD)-MINISTRY OF HEALTH, Temasek Life Sciences Laboratory LimitedInventors: Hong Liang QIAN, Fang HE, Siti Fadilah SUPARI, Hwei-Sing KWANG
-
Patent number: 8540996Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: GrantFiled: September 11, 2012Date of Patent: September 24, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
-
Publication number: 20130243792Abstract: Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections.Type: ApplicationFiled: March 7, 2013Publication date: September 19, 2013Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Theodorus H.J. Kwaks
-
Patent number: 8524231Abstract: The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.Type: GrantFiled: August 8, 2011Date of Patent: September 3, 2013Assignee: Argen-X B.V.Inventors: Torsten Dreier, Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
-
Publication number: 20130202617Abstract: The present invention relates to a novel, isolated and purified hemorrhagic feline calicivirus FCV-DD1. The invention further embraces monovalent and multivalent vaccines containing the new FCV-DD1 strain. In addition, the invention encompasses methods of protecting felines against infection or preventing disease caused by feline calicivirus or in addition to other pathogens that comprises administering to the felines an immunologically effective amount of the monovalent and multivalent vaccines described herein. Also, the invention concerns methods for diagnosing or detecting the hemorrhagic feline calicivirus in a susceptible host, asymptomatic carrier and the like by detecting the presence of feline calicivirus FCV-DD1 or antibodies raised or produced against feline calicivirus FCV-DD1 antigen.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: Boehringer Ingelheim Vetmedica, Inc.Inventors: Chengjin Michael HUANG, Jennifer Hess
-
Publication number: 20130189279Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.Type: ApplicationFiled: April 7, 2011Publication date: July 25, 2013Applicant: Agency for Science, Technology and ResearchInventors: Lucile Warter, Jean-Pierre Abastado, Alessandra Nardin, Cheng-I Wang
-
Publication number: 20130177573Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.Type: ApplicationFiled: July 8, 2011Publication date: July 11, 2013Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
-
Publication number: 20130171131Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: ApplicationFiled: June 22, 2012Publication date: July 4, 2013Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20130171169Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130171132Abstract: This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses.Type: ApplicationFiled: June 22, 2012Publication date: July 4, 2013Inventors: Christopher C. Broder, Katharine N. Bossart
-
Publication number: 20130172536Abstract: The present invention discloses an intravenous cytomegalovirus human immune globulin and a manufacturing method thereof, wherein the technical problem to be solved is to improve the purity, yield, and safety of the product. The intravenous cytomegalovirus human immune globulin of the present invention has a specific activity of no less than 2.5 PEI-U/mg, an anti-CMV titer of no less than 100 PEI-U/ml, a purity of greater than 98.2%, and a protein content of 51˜55 mg/ml.Type: ApplicationFiled: August 16, 2011Publication date: July 4, 2013Applicant: SHENZHEN WEIGUANG BIOLOGICAL PRODUCTS CO.,LTD.Inventors: Yunjia Zhang, Caiping Guo, Yujiang Ding, Qingshuang Song, Xin Zhang, Jincai Wang, Enying Wu, Pei Zhang, Yuqin Chen, Hui Li, Weirong Huang, Meilan Dai, Yanpeng Zhang, Chunhua Wang, Shan Luo, Qiaoyun Huang, Yongdi Liu, Kaiyong Wu
-
Publication number: 20130164307Abstract: The invention provides methods, compositions, and kits featuring a camelid-derived antibody for use in preventing or inhibiting a viral infection.Type: ApplicationFiled: June 17, 2011Publication date: June 27, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Richard B. Markham
-
Publication number: 20130129683Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.Type: ApplicationFiled: May 9, 2011Publication date: May 23, 2013Applicant: Deutsches KrebforschungszentrumInventors: Jürg Nüesch, Nadja Thomas, Claudia Plotzky, Jean Rommelaere
-
Publication number: 20130129747Abstract: The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies. Further provided are novel antibodies against influenza.Type: ApplicationFiled: July 22, 2011Publication date: May 23, 2013Inventor: John W. Schrader
-
Patent number: 8444986Abstract: Monoclonal antibodies and related binding proteins that are specific for conformational epitopes of avian influenza virus K5 subtype hemagglutinin glycoprotein are provided. The antibodies can be used for the detection and treatment of H5 subtype AIV in specimens.Type: GrantFiled: August 26, 2008Date of Patent: May 21, 2013Assignee: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Siti Fadilah Supari, Hwei-Sing Kwang
-
Publication number: 20130108618Abstract: Disclosed are compositions, antibodies, and methods for binding intracellular antigens.Type: ApplicationFiled: October 29, 2012Publication date: May 2, 2013Applicant: University of MarylandInventor: University of Maryland
-
Publication number: 20130101604Abstract: The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130084301Abstract: Compositions and methods are provided relating to human anti-HCV E2 monoclonal antibodies. The antibodies of the invention bind to a conserved region of HCV E2 protein, and neutralize HCV influenza virus across multiple HCV genotypes. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the human anti-HCV monoclonal antibodies; and cell lines that produce these monoclonal antibodies.Type: ApplicationFiled: August 30, 2012Publication date: April 4, 2013Inventors: Steven Foung, Zhen-Yong Keck
-
Publication number: 20130071424Abstract: The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1.Type: ApplicationFiled: September 12, 2012Publication date: March 21, 2013Applicant: NEW YORK UNIVERSITYInventors: Timothy CARDOZO, Xiangpeng KONG, Susan ZOLLA-PAZNER
-
Publication number: 20130058968Abstract: The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal.Type: ApplicationFiled: October 4, 2010Publication date: March 7, 2013Inventors: W. Ian Lipkin, Gustavo Palacios, Ruth Toril Kongtorp, Edgar Brun
-
Publication number: 20130058952Abstract: The invention relates to an anti-HSV antibody as defined in the claims, a pharmaceutical composition comprising of an effective amount of the said antibody, an expression vector comprising of a nucleotide sequence which encodes the said antibody, a host cell comprising of the said nucleotide sequence, a hybridoma cell capable of producing the said antibody and the use of the said antibody as a drug, in particular to use for the manufacture of a drug for the prophylactical or therapeutical treatment of HSV-associated diseases in a subject; as defined in the claims.Type: ApplicationFiled: October 1, 2010Publication date: March 7, 2013Inventors: Michael Roggendorf, Anna-Maria Eis-Hübinger, Jürgen Krauss, Karl Eduard Schneweis, Edelgard Schneweis, Michaela Arndt, Adalbert Krawczyk, Evelyn Exner, Martin P. Däumer
-
Publication number: 20130052634Abstract: Replicons of genotype 4 hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 4 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: ApplicationFiled: July 5, 2012Publication date: February 28, 2013Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Betty Peng
-
Publication number: 20130052633Abstract: Replicons of genotype 3 of hepatitis C virus (HCV) are provided. These replicons contains adaptive mutations giving rise to the HCV's capability to replicate in vitro. Methods of preparing genotype 3 replicons and methods of using these replicons to screen antiviral agents are also provided.Type: ApplicationFiled: July 5, 2012Publication date: February 28, 2013Applicant: Gilead Sciences, Inc.Inventors: William E. Delaney, IV, Guofeng Cheng, Hongmei Mo, Simin Xu, Mei Yu, Amoreena Corsa
-
Publication number: 20130052163Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.Type: ApplicationFiled: August 28, 2012Publication date: February 28, 2013Applicant: Theraclone Sciences, Inc.Inventor: Po-Ying Chan-Hui
-
Publication number: 20130028913Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.Type: ApplicationFiled: December 1, 2010Publication date: January 31, 2013Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
-
Publication number: 20130022619Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.Type: ApplicationFiled: April 11, 2011Publication date: January 24, 2013Inventors: Grant Thomas Rawlin, Damian Francis John Purcell, Robert John Center, Marit Kramski, Roy Michael Robins-Browne, Gottfried Lichti
-
Publication number: 20130022618Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: ApplicationFiled: September 10, 2012Publication date: January 24, 2013Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINEInventors: Antonio LANZAVECCHIA, Annalisa MACAGNO
-
Publication number: 20130011414Abstract: Provided herein are HIV-1-specific transforming antibodies (tAbs) and antigens that are recognized by HIV-1-specific tAbs. Also provided herein are methods for screening and/or generating HIV-1-specific tAbs and uses of tAbs for prevention and treatment of HIV-1 infection.Type: ApplicationFiled: June 27, 2012Publication date: January 10, 2013Applicant: University of Hong KongInventor: Mei-Yun Zhang
-
Publication number: 20130011388Abstract: A concentrated, immunoglobulin composition for treating subjects vaccinated against or infected with a pathogenic microorganism, is made by (a) selecting a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism; (b) identifying very high titre individuals by determining the level of specific antibodies immunoreactive with the pathogenic microorganism in the blood of the individuals; (c) combining blood from the very high titre individuals; and (d) purifying and/or concentrating the product of step (c). A concentrated immunoglobulin composition can include specific antibodies immunoreactive with a pathogenic microorganism, wherein the titre of specific antibodies is at least 5 times higher than the average titre of specific antibodies of a population of individuals previously vaccinated against antigens associated with the pathogenic microorganism. The composition has a relatively high protein concentration and a low percentage of protein aggregates.Type: ApplicationFiled: September 14, 2012Publication date: January 10, 2013Applicant: Omrix Biopharmaceuticals Ltd.Inventors: Israel Nur, Liliana Bar, Orgad Laub
-
Publication number: 20130004944Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embeded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides means for the diagnosis and surveillance of dangerous viral infections.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Applicant: Tamasek Life Sciences Laboratory LimitedInventors: Yuen Fern HO, Qing Yun DU, Fang HE, Jimmy Hwei-Sing KWANG
-
Publication number: 20130004497Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Applicant: Temasek Life Sciences Laboratory LimitedInventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang